These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32691140)

  • 41. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
    J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
    Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
    Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
    Lombardi C; Comberiati P; Ridolo E; Cottini M; Yacoub MR; Casagrande S; Riccò M; Bottazzoli M; Berti A
    Drugs; 2024 Jun; 84(6):661-684. PubMed ID: 38849701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
    Domingo C
    Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma.
    Lommatzsch M; Marchewski H; Schwefel G; Stoll P; Virchow JC; Bratke K
    Clin Exp Allergy; 2020 Nov; 50(11):1267-1269. PubMed ID: 32762056
    [No Abstract]   [Full Text] [Related]  

  • 48. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
    Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
    J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab.
    Bergantini L; d'Alessandro M; Cameli P; Bianchi F; Sestini P; Bargagli E; Refini RM
    Int Arch Allergy Immunol; 2020; 181(10):746-753. PubMed ID: 32731216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
    J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
    Al Efraij K; FitzGerald JM
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
    Ghassemian A; Park JJ; Tsoulis MW; Kim H
    Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma.
    Chia YL; Yan L; Yu B; Wang B; Barker P; Goldman M; Roskos L
    Clin Pharmacol Ther; 2019 Aug; 106(2):383-390. PubMed ID: 30661249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment.
    Vantaggiato L; Cameli P; Bergantini L; d'Alessandro M; Shaba E; Carleo A; Di Giuseppe F; Angelucci S; Sebastiani G; Dotta F; Bini L; Bargagli E; Landi C
    Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unsustained Response to Benralizumab in Eosinophilic Asthma After 3 Years of Therapy With Mepolizumab.
    Kurosawa M; Shimizu Y; Sutoh Y; Sutoh E
    J Investig Allergol Clin Immunol; 2021 Jul; 31(4):353-355. PubMed ID: 33136004
    [No Abstract]   [Full Text] [Related]  

  • 58. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
    Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
    Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
    Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
    Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.